ORKA Oruka Therapeutics, Inc. Common Stock Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
16:43
Apr 29
A May MD
Bearish view on ORKA on ABBV's advancing extended half-life IL23.
Bearish view on ORKA on ABBV's advancing extended half-life IL23, adding another competitor that reduces ORKA's market opportunity in a crowded space.
ORKA Oruka Therapeutics, Inc. Common Stock Avoid — —
10:57
Apr 29
A May MD
Bearish view on ORKA as a me-too psoriasis drug with no meaningful innovation.
Bearish view on ORKA as a me-too psoriasis drug with no meaningful innovation; high valuation ($6B) relies on broken payor system and is unsustainable long-term.
ORKA Oruka Therapeutics, Inc. Common Stock Avoid — —
01:14
Apr 29
A May MD
Bearish view on ORKA at current valuation because its $6B market cap at Phase 2a implies peak.
Bearish view on ORKA at current valuation because its $6B market cap at Phase 2a implies peak sales exceeding Bimzelx (~$3B), an absurd premium for an unproven asset with no near-term revenue.
ORKA Oruka Therapeutics, Inc. Common Stock Avoid — —
Log in to see ideas

About ORKA Investor Commentary

Across the available history and selected sources, Buzzberg tracks ORKA (Oruka Therapeutics, Inc. Common Stock) across 2 sources: 1 bullish vs 2 bearish calls from 2 authors. Historical directional balance: -3% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 32 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: A May MD.